阿替利珠单抗联合贝伐珠单抗及化疗治疗EGFR或ALK突变非小细胞肺癌的III期随机研究(ATTLAS,KCSG-LU19-04)
这项随机、开放标签、多中心III期研究纳入228例EGFR突变(215例)或ALK易位(13例)且TKI治疗进展的NSCLC患者,按2:1随机接受ABCP方案(154例)或PC方案(74例)。ABCP组客观缓解率(69.5% vs 41.9%,P<.001)和中位无进展生存期(8.48 vs 5.62个月,HR 0.62,95%CI 0.45-0.86,P=.004)显著优于PC组,总生存无显著差异(20.63 vs 20.27个月,HR 1.01,95%CI 0.69-1.46,P=.975)。
要点
- ABCP组中位PFS 8.48个月 vs PC组5.62个月,HR 0.62(95%CI 0.45-0.86),P=.004。
- ABCP组客观缓解率69.5% vs PC组41.9%,P<.001。
- PD-L1表达越高PFS获益越大,PD-L1≥1%、≥10%、≥50%的HR分别为0.47、0.41、0.24。
核心结论
- 研究首次在随机III期研究中证实,对EGFR或ALK突变且靶向治疗进展的NSCLC患者,抗PD-L1抗体联合贝伐珠单抗及化疗具有临床获益。
研究设计与样本
- 随机、开放标签、多中心III期研究,纳入228例EGFR突变(215例)或ALK易位(13例)NSCLC患者,来自韩国16个中心,按2:1随机分配至ABCP组(154例)或PC组(74例)。
- ABCP方案为阿替利珠单抗+贝伐珠单抗+紫杉醇+卡铂,后续阿替利珠单抗+贝伐珠单抗维持治疗;PC方案为培美曲塞+卡铂或顺铂,后续培美曲塞维持治疗。
- 主要终点为无进展生存期(PFS)。
主要发现
- ABCP组客观缓解率69.5% vs PC组41.9%,P<.001。
- ABCP组中位PFS 8.48个月 vs PC组5.62个月,HR 0.62(95%CI 0.45-0.86),P=.004。
- PD-L1≥1%、≥10%、≥50%亚组的PFS HR分别为0.47、0.41、0.24。
- 两组总生存相似:ABCP组20.63个月 vs PC组20.27个月,HR 1.01(95%CI 0.69-1.46),P=.975。
- ABCP组治疗相关不良事件发生率高于PC组,安全性特征与既往报道相当,无额外安全信号。
关键数值与推荐
- ABCP组客观缓解率69.5% vs PC组41.9%,P<.001。
- ABCP组中位PFS 8.48个月 vs PC组5.62个月,HR 0.62(95%CI 0.45-0.86),P=.004。
- PD-L1≥1%、≥10%、≥50%的PFS HR分别为0.47、0.41、0.24。
- ABCP组中位OS 20.63个月 vs PC组20.27个月,HR 1.01(95%CI 0.69-1.46),P=.975。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the treatment of non-small-cell lung cancer (NSCLC) with a driver mutation, the role of anti-PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-mutated NSCLC that progressed before TKI therapy. MATERIALS AND METHODS: We compared the clinical efficacy of ABCP followed by maintenance therapy with atezolizumab plus bevacizumab with pemetrexed plus carboplatin or cisplatin (PC) followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). RESULTS: A total of 228 patients with activating EGFR mutation (n = 215) or ALK translocation (n = 13) were enrolled from 16 sites in the Republic of Korea and randomly assigned at 2:1 ratio to either ABCP (n = 154) or PC arm (n = 74). The median follow-up duration was 26.1 months (95% CI, 24.7 to 28.2). Objective response rates (69.5% v 41.9%, P < .001) and median PFS (8.48 v 5.62 months, hazard ratio [HR], 0.62 [95% CI, 0.45 to 0.86]; P = .004) were significantly better in the ABCP than PC arm. PFS benefit increased as PD-L1 expression increased, with an HR of 0.47, 0.41, and 0.24 for PD-L1 ≥1%, ≥10%, and ≥50%, respectively. Overall survival was similar between ABCP and PC arm (20.63 v 20.27 months, HR, 1.01 [95% CI, 0.69 to 1.46]; P = .975). The safety profile of the ABCP arm was comparable with that previously reported, with no additional safety signals, but higher rates of treatment-related adverse events were observed compared with the PC arm. CONCLUSION: To our knowledge, this study is the first randomized phase III study to demonstrate the clinical benefit of anti-PD-L1 antibody in combination with bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated NSCLC who have progressed on relevant targeted therapy.
引用
- Park S, Kim TM, Han JY, et al. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2023. PMID: 37861993. doi:10.1200/JCO.23.01891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。